Details of the Drug Combination

General Information of Drug Combination (ID: DCSCWO4)

Drug Combination Name
NABILONE Dantrolene
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs NABILONE   DMVRYT2 Dantrolene   DM1D8XY
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 11.75
Bliss Independence Score: 11.75
Loewe Additivity Score: 14.84
LHighest Single Agent (HSA) Score: 14.84

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of NABILONE
Disease Entry ICD 11 Status REF
Insomnia 7A00-7A0Z Approved [2]
NABILONE Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cannabinoid receptor 2 (CB2) TTMSFAW CNR2_HUMAN Inhibitor [4]
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Indication(s) of Dantrolene
Disease Entry ICD 11 Status REF
Hyperthermia MG26 Approved [3]
Dantrolene Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Ryanodine receptor (RYR) TT9YXM1 NOUNIPROTAC Modulator [5]
------------------------------------------------------------------------------------
Dantrolene Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4172).
4 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.